Ironwood Pharmaceuticals (NASDAQ:IRWD) Lowered to “Buy” Rating by StockNews.com

StockNews.com cut shares of Ironwood Pharmaceuticals (NASDAQ:IRWD) from a strong-buy rating to a buy rating in a research report sent to investors on Tuesday.

A number of other brokerages have also recently commented on IRWD. Leerink Partners started coverage on Ironwood Pharmaceuticals in a research note on Monday, September 9th. They set a “market perform” rating and a $5.00 price objective for the company. Wells Fargo & Company cut their price target on shares of Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating on the stock in a research report on Friday, August 9th. Craig Hallum decreased their price objective on shares of Ironwood Pharmaceuticals from $14.00 to $10.00 and set a “buy” rating for the company in a report on Friday, August 9th. Leerink Partnrs raised shares of Ironwood Pharmaceuticals to a “hold” rating in a report on Monday, September 9th. Finally, Capital One Financial cut shares of Ironwood Pharmaceuticals from an “overweight” rating to an “equal weight” rating and lowered their price objective for the company from $12.00 to $4.00 in a research report on Thursday, August 8th. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.40.

Ironwood Pharmaceuticals Trading Down 8.1 %

Shares of IRWD stock opened at $4.40 on Tuesday. Ironwood Pharmaceuticals has a 12 month low of $3.79 and a 12 month high of $15.70. The stock has a 50-day moving average price of $4.32 and a 200 day moving average price of $5.55.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.07). Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The business had revenue of $91.60 million for the quarter, compared to analyst estimates of $91.22 million. During the same quarter in the prior year, the firm earned $0.12 EPS. The firm’s quarterly revenue was down 19.4% compared to the same quarter last year. Equities analysts forecast that Ironwood Pharmaceuticals will post 0.1 EPS for the current fiscal year.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in IRWD. Texas Permanent School Fund Corp boosted its position in shares of Ironwood Pharmaceuticals by 1.3% during the first quarter. Texas Permanent School Fund Corp now owns 120,245 shares of the biotechnology company’s stock worth $1,047,000 after buying an additional 1,557 shares during the period. CWM LLC boosted its holdings in Ironwood Pharmaceuticals by 55.1% during the second quarter. CWM LLC now owns 6,600 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 2,345 shares during the last quarter. Louisiana State Employees Retirement System grew its position in Ironwood Pharmaceuticals by 3.5% in the second quarter. Louisiana State Employees Retirement System now owns 70,400 shares of the biotechnology company’s stock valued at $459,000 after purchasing an additional 2,400 shares in the last quarter. SummerHaven Investment Management LLC increased its stake in Ironwood Pharmaceuticals by 3.6% in the 2nd quarter. SummerHaven Investment Management LLC now owns 72,030 shares of the biotechnology company’s stock valued at $470,000 after buying an additional 2,491 shares during the last quarter. Finally, Rhumbline Advisers increased its stake in Ironwood Pharmaceuticals by 0.7% in the 2nd quarter. Rhumbline Advisers now owns 365,701 shares of the biotechnology company’s stock valued at $2,384,000 after buying an additional 2,577 shares during the last quarter.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.